Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aa48a431ce250933eb0fdd7a1caf3f30 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-703 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7084 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0021 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-726 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-727 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-715 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-721 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-662 |
filingDate |
2013-07-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d492934a83dbf376f327c1301c72f5eb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a4f1544f3624af3242209fc2ce524dec http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6d193fa34cda176bb563e7bd086df98e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7cc424907bf8153c3460668697e6da50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4d40265b5e9f27fe0c37afb00f06ec82 |
publicationDate |
2013-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
JP-2013256500-A |
titleOfInvention |
Methods for suppressing reduction in transdermal drug flow by inhibiting pathway closure |
abstract |
The present invention provides a method for suppressing a decrease in transdermal flow of an active substance in transdermal administration of the active substance. The method comprises: causing disintegration in at least the stratum corneum of the skin to form a plurality of pathways; causing a first agent and at least one anti-healing agent to flow through the pathways. A method of inhibiting a decrease in transdermal flow of a first agent comprising: wherein the skin disruption is a microslit caused by microprojections penetrating one or more stratum corneum. [Selection] Figure 8 |
priorityDate |
2000-09-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |